Clinical Trial: A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs

U.S., April 4 -- ClinicalTrials.gov registry received information related to the study (NCT06908928) titled 'A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs' on March 20.

Brief Summary: The goal of this clinical trial is to investigate if treatment with bulumtatug fuvedotin is effective in triple-negative breast cancer patients who have previously received treatment with an antibody-drug conjugates.

Study Start Date: May, 2025

Study Type: INTERVENTIONAL

Condition: Triple Negative Breast Cancer

Intervention: DRUG: bulumtatug fuvedotin

given via intravenous infusion on day 1 and day 8 of every 21-day cycle at dose level 1

DRUG: bulumtatug fuvedotin

given via intravenous infusion on da...